-
SK Inc. Liquidates SK Biopharmaceuticals Stake in PRS Deal
26 Feb 2026 14:03 GMT
SK Inc., the holding company of SK Group, will sell approximately 1.25 trillion won or $866 million worth of its stake in subsidiary SK Biopharm to secure investment funds and improve its financial structure.
Notably, SK Inc. has opted not for a simple …
-
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q4 2025 Earnings Call Transcript
25 Feb 2026 13:30 GMT
… February 24, 2026
Day One Biopharmaceuticals, Inc. misses on earnings expectations … advancements. Together, the Day One Biopharmaceuticals, Inc. team achieved seminal commercial … your participation.
Follow Day One Biopharmaceuticals Inc. (NASDAQ:DAWN) Follow …
-
Advances in Cell Line Development and Production of Novel Modalities in Biopharmaceutical Manufacturing
24 Feb 2026 16:56 GMT
… solutions are converging to accelerate biopharmaceutical development.
Attend this webinar … of Novel Modalities in Biopharmaceutical Manufacturing
As demand for … solutions are converging to accelerate biopharmaceutical development.
Attend this webinar …
-
Drug Platform Accelerates Biopharmaceutical Therapy Development
24 Feb 2026 16:56 GMT
Daily Breaking Science News
Tailored newsletters
Exclusive eBooks, infographics and online events
Subscribe Now
Scientists have developed an adaptable materials platform that can safely and efficiently deliver a wide range of genetic medicines, a …
-
Examining the Future: Day One Biopharmaceutical';s Earnings Outlook
23 Feb 2026 20:22 GMT
…
Analyst Opinions on Day One Biopharmaceutical
Understanding market sentiments and expectations … insights on Day One Biopharmaceutical.
Day One Biopharmaceutical has received a total … releases for Day One Biopharmaceutical visit their earnings calendar on …
-
Azitra, Inc. Announces Full Year 2025 Results and Provides Business Updates
27 Feb 2026 22:56 GMT
… American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative … , Inc. is a clinical stage biopharmaceutical company focused on developing innovative …
-
Choose New Jersey Marks 15 Years of Growth, Delivers $1B Economic Impact in 2025
27 Feb 2026 21:43 GMT
… year include:
Jersey City-based biopharmaceutical company Celltrion expanded its domestic … Branchburg, strengthening New Jersey’s biopharmaceutical and advanced manufacturing base.
CoreWeave …
-
XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing
27 Feb 2026 21:30 GMT
… , 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB … for continued listing. About XTL Biopharmaceuticals Ltd. XTL is an IP … , please contact: Investor Relations, XTL Biopharmaceuticals Ltd.
Tel: +972 3 611 …
-
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older
27 Feb 2026 22:57 GMT
…
Ascendis Pharma is a global biopharmaceutical company focused on applying our …
-
What Are the Common Challenges in Biologics Process Development?
28 Feb 2026 00:28 GMT
… substance process. That requirement forces biopharmaceutical process development teams to map …
About
© 1995-2026